Back to Search

ATXS

Astria Therapeutics, Inc. Common Stock
Data: 2026-01-22
$12.58
Price
0.64%
Change
$13.285
52W High
$3.555
52W Low
Buy/Sell Forecast Trendline Why Moving Charts Options

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Quick Stats

57.7

AI Score

HOLD

4.31

Volume Ratio

Next Earnings

14

+ve Days (30d)

14

-ve Days (30d)

ATXS Stock Summary

Last updated

ATXS is currently trading at $12.58, positioned below its 200-day moving average of $, suggesting bearish momentum. The stock has a 52-week range of $3.555 to $13.285.

Technical Analysis: The 50-day moving average stands at $, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads , suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is , which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates ATXS at 57.7/100 with a HOLD recommendation.

ATXS Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

ATXS Price vs Max Options Open Interest
ATXS Max Change In Options Open Interest

ATXS Options - Sort by Max open Interest (near term)

3rd February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

ATXS Daily Out of Money Options - Sort by Max open Interest (near term)

3rd February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

ATXS Daily In the Money Options - Sort by Max open Interest (near term)

3rd February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

ATXS Most Active Options by Volume(near term)

3rd February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI		 Ask PC Delta Vega Volatility % change Track

Astria Therapeutics, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

ATXS Moving Averages Analysis

ATXS (Astria Therapeutics, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated

Days MA

ATXS Fundamental Analysis

P/E (Forward) 0
P/E (Trailing) --
Market Cap ($) 713.6 million
Earnings/Share ($) -2.14
Net Proft Margin (%) 0
Dividend/Share ($) --
EPS Estimate Current Year ($) -2.1233
EPS Estimate Next Year ($) -2.3575
WallStreet Target Price ($) 24.6
Most Recent Quarter